Get the Stockscreener App
16.07
0.56%
0.09
Immunome Inc stock is traded at $16.07, with a volume of 732.90K.
It is up +0.56% in the last 24 hours and up +37.23% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$15.98
Open:
$15.93
24h Volume:
732.90K
Relative Volume:
0.59
Market Cap:
$1.40B
Revenue:
$12.59M
Net Income/Loss:
$-212.39M
P/E Ratio:
-5.2086
EPS:
-3.0853
Net Cash Flow:
$-185.92M
1W Performance:
+2.42%
1M Performance:
+37.23%
6M Performance:
+82.82%
1Y Performance:
+40.10%
1-Day Range:
$15.64
$16.43
1-Week Range:
$15.36
$17.20
52-Week Range:
$5.1501
$17.32
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
16.07 | 1.39B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Will Immunome Inc. stock reach Wall Street targets2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Using economic indicators to assess Immunome Inc. potentialJuly 2025 Price Swings & Verified Momentum Stock Watchlist - newser.com
Is Immunome Inc. stock a safe haven assetTrade Analysis Summary & Target Return Focused Picks - newser.com
Historical volatility pattern of Immunome Inc. visualizedShare Buyback & Verified Trade Idea Suggestions - newser.com
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference - The AI Journal
Is Immunome Inc. stock bottoming outJuly 2025 Price Swings & Fast Entry Momentum Trade Alerts - newser.com
What technical signals suggest for Immunome Inc. stock2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
Immunome Bets Big On Cancer Drugs As Shares Outpace The Market - Finimize
Evaluating Immunome Inc. with trendline analysis2025 Historical Comparison & Weekly Setup with High ROI Potential - newser.com
How Immunome Inc. stock benefits from tech adoptionWeekly Investment Recap & Smart Investment Allocation Tips - newser.com
Aug Highlights: How Immunome Inc. stock benefits from tech adoptionMarket Activity Recap & Fast Moving Stock Trade Plans - fcp.pa.gov.br
Immunome (NASDAQ:IMNM) Trading 8.3% HigherTime to Buy? - MarketBeat
Will Immunome Inc. stock outperform Nasdaq indexInsider Selling & Proven Capital Preservation Tips - fcp.pa.gov.br
Can Immunome Inc. stock beat analyst upgradesEarnings Summary Report & Free High Accuracy Swing Entry Alerts - fcp.pa.gov.br
Why Immunome Inc. stock is popular among millennialsLayoff News & AI Driven Stock Price Forecasts - fcp.pa.gov.br
Can machine learning forecast Immunome Inc. recoveryJuly 2025 PostEarnings & High Yield Stock Recommendations - newser.com
Immunome’s Phase 1 Cancer Study: A Potential Game-Changer? - TipRanks
Chart overlay techniques for tracking Immunome Inc.Weekly Profit Report & Community Trade Idea Sharing - newser.com
How Immunome Inc. stock performs in rate cut cycles2025 Bull vs Bear & Smart Money Movement Tracker - newser.com
Immunome's (IMNM) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
| Tsai Philip | Chief Technology Officer |
Mar 24 '25 |
Buy |
8.42 |
12,300 |
103,566 |
33,300 |
| SIEGALL CLAY B | President and CEO |
Jan 31 '25 |
Buy |
7.75 |
150,000 |
1,162,500 |
669,636 |
| SIEGALL CLAY B | President and CEO |
Nov 21 '24 |
Buy |
9.54 |
66,057 |
630,263 |
485,693 |
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):